Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae
Authors:
Open Access
- 16 January 2017
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (3) , 1003-1010
Abstract
The aim of the present study was to compare the efficacy and safety of fosfomycin combinational therapy with other antibiotics for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This retrospective cohort study examined 104 cases of sepsis caused by CRKP occurring between January 2012 and November 2014 in Shanghai Tenth People's Hospital. Three categories of patient outcome were assessed: Survival/mortality, duration of intensive care unit stays and duration of medical ventilation. Univariate ordinal analyses were adopted to evaluate the correlations between outcome and treatment. A total of 104 patients with physician-diagnosed CRKP were involved in the study. The overall mortality rate was 25.0%. The majority of the infections (84; 80.8%) were hospital acquired. Critical infections received more than one active antibiotic as therapy. Patients treated with fosfomycin combinational therapy were less likely to fail therapy (OR: 4.71, 95% CI: 1.03–21.65, P=0.034) and tended to have a shorter duration of mechanical ventilation. Gender (OR: 4.35, 95% CI: 1.08–3.60, P=0.037), history of chronic obstructive pulmonary disease (OR: 9.35, 95% CI: 0.06–0.19, P=0.007) and peripheral catheter use (OR: 3.00, 95% CI: 0.07–0.19, P=0.002) are risk factors for clinical outcome. Therefore, the use of fosfomycin combinational therapy for treatment of infection due to CRKP appears to be associated with improved survival rate.Keywords
This publication has 26 references indexed in Scilit:
- Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniaeFrontiers in Microbiology, 2016
- Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesDiagnostic Microbiology and Infectious Disease, 2013
- Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global DimensionsClinical Microbiology Reviews, 2012
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial RegimensAntimicrobial Agents and Chemotherapy, 2012
- Treatment of Klebsiella Pneumoniae Carbapenemase (KPC) infections: a review of published case series and case reportsAnnals of Clinical Microbiology and Antimicrobials, 2012
- Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatmentClinical Microbiology and Infection, 2011
- Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?Clinical Microbiology and Infection, 2011
- Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assayInternational Journal of Antimicrobial Agents, 2011
- Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection controlClinical Microbiology and Infection, 2010
- Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae BacteremiaInfection Control & Hospital Epidemiology, 2009